BlackRock, Inc. 13D and 13G filings for Heron Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Heron Therapeutics, Inc. HRTX | BlackRock Inc. BLK | 8,534,567 5.600% | 0 (Unchanged) | Filing |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Heron Therapeutics, Inc. HRTX | BlackRock Inc. BLK | 8,534,567 5.600% | 1,497,253 (+21.28%) | Filing |
| 2023-12-06 4:47 pm Sale | 2023-11-30 | 13G | Heron Therapeutics, Inc. HRTX | BlackRock Inc. BLK | 7,037,314 4.700% | -2,613,395 (-27.08%) | Filing |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | Heron Therapeutics, Inc. HRTX | BlackRock Inc. BLK | 9,650,709 8.100% | 1,968,508 (+25.62%) | Filing |
| 2022-02-01 5:08 pm Purchase | 2021-12-31 | 13G | Heron Therapeutics, Inc. HRTX | BlackRock Inc. BLK | 7,682,201 7.500% | 795,269 (+11.55%) | Filing |
| 2021-01-29 09:56 am Purchase | 2020-12-31 | 13G | Heron Therapeutics, Inc. HRTX | BlackRock Inc. BLK | 6,886,932 7.600% | 1,118,730 (+19.39%) | Filing |
| 2020-02-05 11:45 am Purchase | 2019-12-31 | 13G | Heron Therapeutics, Inc. HRTX | BlackRock Inc. BLK | 5,768,202 6.400% | 855,196 (+17.41%) | Filing |